Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...

For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

“Vedolizumab treatment prevented postoperative recurrence of Crohn’s disease following ileocolonic ... or owning stock or stock options in Takeda or other pharmaceutical companies.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

“We are in a time where biosimilars for Crohn’s disease and ulcerative colitis ... patients needing these medications and expand options for treatment.” Looking into 2025, Regueiro added ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...